Literature DB >> 10633011

Expression of apoptosis-associated genes by human dermal scar fibroblasts.

D V Messadi1, A Le, S Berg, A Jewett, Z Wen, P Kelly, C N Bertolami.   

Abstract

The purpose of this study was to determine if aberrant apoptosis plays a role in pathologic wound healing as manifested by hypertrophic scarring and keloid formation. Apoptosis has recently been found to participate in the transition between granulation tissue and the development of definitive scar. The question that remains to be answered is what stimuli initiate apoptosis during wound healing. Hitherto, regulatory factors and pathways involved have been largely undefined. We investigated heterogeneity among fibroblasts derived from normal skin and keloid scar, by examining apoptotic profiles and pathways for these cells. Quantitative analysis of apoptotic cells using an Annexin-V-FITC binding assay showed that normal skin fibroblast cultures were found to have a two-fold higher percentage of apoptotic cells than did keloid fibroblast cultures. To study apoptotic pathways and related death-associated genes, a ribonuclease protection assay was performed for fibroblasts exposed to anti-Fas antibody and tumor necrosis factor-alpha to activate the Fas/TNF receptor apoptotic pathway. Compared with normal skin fibroblasts, keloid fibroblasts exhibited decreased expression of apoptosis-associated genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10633011     DOI: 10.1046/j.1524-475x.1999.00511.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  13 in total

1.  Altered fibroblast proliferation and apoptosis in diabetic gingival wounds.

Authors:  T Desta; J Li; T Chino; D T Graves
Journal:  J Dent Res       Date:  2010-03-30       Impact factor: 6.116

2.  [Hyperplastic scars and keloids. Part I: basics and prevention].

Authors:  A Baisch; F Riedel
Journal:  HNO       Date:  2006-11       Impact factor: 1.284

3.  Response of keloid fibroblasts to Vitamin D3 and quercetin treatment - in vitro study.

Authors:  K Mathangi Ramakrishnan; M Babu; M S Lakshmi Madhavi
Journal:  Ann Burns Fire Disasters       Date:  2015-09-30

4.  Increased plasminogen activator inhibitor-1 in keloid fibroblasts may account for their elevated collagen accumulation in fibrin gel cultures.

Authors:  Tai-Lan Tuan; Huayang Wu; Eunice Y Huang; Sheree S N Chong; Walter Laug; Diana Messadi; Paul Kelly; Anh Le
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

5.  Impaired wound healing in mouse models of diabetes is mediated by TNF-alpha dysregulation and associated with enhanced activation of forkhead box O1 (FOXO1).

Authors:  M F Siqueira; J Li; L Chehab; T Desta; T Chino; N Krothpali; Y Behl; M Alikhani; J Yang; C Braasch; D T Graves
Journal:  Diabetologia       Date:  2009-11-10       Impact factor: 10.122

6.  Role of Hyaluronic Acid Treatment in the Prevention of Keloid Scarring.

Authors:  Andrea Hoffmann; Jessica Lynn Hoing; Mackenzie Newman; Richard Simman
Journal:  J Am Coll Clin Wound Spec       Date:  2013-07-01

7.  Differential apoptosis markers in human keloids and hypertrophic scars fibroblasts.

Authors:  Bruna De Felice; Corrado Garbi; Margherita Santoriello; Alessandra Santillo; Robert R Wilson
Journal:  Mol Cell Biochem       Date:  2009-02-18       Impact factor: 3.396

8.  Dermal fibroblast phagocytosis of apoptotic cells: A novel pathway for wound resolution.

Authors:  Bruna Romana-Souza; Lin Chen; Trevor R Leonardo; Zhenlong Chen; Luisa A DiPietro
Journal:  FASEB J       Date:  2021-04       Impact factor: 5.191

Review 9.  Hypertrophic scar formation following burns and trauma: new approaches to treatment.

Authors:  Shahram Aarabi; Michael T Longaker; Geoffrey C Gurtner
Journal:  PLoS Med       Date:  2007-09       Impact factor: 11.069

10.  Phenotypic differences between dermal fibroblasts from different body sites determine their responses to tension and TGFbeta1.

Authors:  Constantin C Chipev; Marcia Simon
Journal:  BMC Dermatol       Date:  2002-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.